Synovial inflammatory cells captured 131I-β2-microglobulin in patients with Dialysis Related Amyloidosis

Amyloid

Volumn 5, Issue 1, 1998, Pages 24-29

  Kazama, Junichiro James ^a   Arakawa, Masaaki ^a   Gejyo, Fumitake ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Dialysis related amyloidosis; Histoautoradiography; Scintigraphy; 2 microglobulin ( 2M)

Indexed keywords

BETA 2 MICROGLOBULIN; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; RADIOACTIVE IODINE;

ADULT; AMYLOIDOSIS; ARTICLE; AUTORADIOGRAPHY; CARPAL TUNNEL SYNDROME; CASE REPORT; CYTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; MALE; METABOLISM; MIDDLE AGED; MONOCYTE; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; SCINTISCANNING; SYNOVIUM;

ADULT; AMYLOIDOSIS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; AUTORADIOGRAPHY; BETA 2-MICROGLOBULIN; CARPAL TUNNEL SYNDROME; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; IODINE RADIOISOTOPES; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; RADIONUCLIDE IMAGING; RENAL DIALYSIS; SYNOVIAL MEMBRANE;

EID: 0032012656     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.3109/13506129809007286     Document Type: Article

References (30)

1. Gejyo F, Honma N and Arakawa M (1993). Long-term complications of dialysis: pathogenetic factors with special reference to amyloidosis. Kidney Int 43, Suppl41: S78-S82
2. 2-microglobulin. Biochem Biophys Res Commun 129, 701-706
3. Sethi D and Gower PE (1986). Synovial fluid beta 2-microglobulin levels in dialysis arthropathy (letter). N Eng J Med 315, 1419-1420
4. Kleinman KS and Coburn JW (1989). Amyloid syndromes associated with hemodialysis. Kidney Int 35, 567-573
5. Koch KM (1992). Dialysis-related amyloidosis. Kidney Int 41, 1416-1429
6. Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, Pugh CW, Winearls CG, Oliver DO and Pepys MB (1991). Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component. Lancet 338, 335-339
7. 2-microglobulin. Kidney Int 38, 1169-1176
8. 2-microglobulin scintigraphy in patients with dialysis amyloidosis. Clin Nephrol 44, S14-S18
9. Hunter WM and Greenwood FC (1962). Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 194, 495-496
10. Kazama JJ, Takeda T, Katagiri T, Kuwano R, Kumanishi T, Ozawa H and Arakawa M (1995). A histocytochemical study of spot 35-calbindin-D28K in rat kidney Nephrology 1, 73-82
11. Kazama JJ, Gejyo F, Ejiri S, Okada M, Ei I, Arakawa M and Ozawa H (1993). Application of confocal laser scanning microscopy to the observation of bone biopsy specimens. Bone 14, 885-889
12. Argiles A, Mourad G, Kerr PG, Garcia M, Collins B and Demaille JG (1994). The cells surrounding haemodialysis associated amyloid deposits are mainly macrophages. Nephrol Dial Transp 9, 662-667
13. Ohashi K, Hara M, Kawai R, Ogura Y, Honda K, Nihei H and Mimura N (1992). Cervical discs are most susceptible to beta2-microglobulin amyloid deposition in the vertebral column. Kidney Int 41, 1646-1652
14. Niwa T, Miyazaki S, Katsuzaki T, Tatemichi N, Takei Y, Miyazaki T, Morita T and Hirasawa Y (1995). Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 48, 771-778
15. Gejyo F, Maruyama H, Teramura T, Kazama JJ, Ei I and Arakawa M (1995). Role of macrophages in β2-microglobulin-related dialysis amyloidosis. Contrib Nephrol 112, 97-104
16. Floege J and Ehlerding G (1996). Beta-2-microglobulin-associated amyloidosis. Nephron 72, 9-26
17. Rainsbouly R (1983). Location of metastatic breast carcinoma by a monoclonal antibody chelate labeled with indium-111. Lancet :ii 934-938
18. Schaeffer J, Floege J and Koch KM ( 1996) Whole-body scintigraphy. In van Ypersele C and Drueke TB (ed.) Dialysis Amyloid, pp145-155. (New York and London FOxford University)
19. Jadoul M, Noel H, Malghem J, Galant C and van Ypersele C (1996). Histological beta-2-microglobulin amyloidosis 10 years after a successful renal transplantation. Ame J Kid Dis 27, 888-890
20. 2-microglobulin turnover in dialyzed patients. Kidney Int 42, 1434-1443
21. Chanard J, Vincent C, Caudwell V, Lavaud S, Wong T and Revillard J-P (1993). Beta 2-microglobulin metabolism in uremic patients who are undergoing dialysis. Kidney Int 43, Suppl 41: S83-S87
22. Nguyen-Simonnet H, Vincent C, Gauthier C, Revillard JP and Pellet MV (1982). Turnover studies of human β2-m in the rat. JClin Sci 62, 403-410
23. Brownlee M (1994). Glycation and diabetic complications. Diabetes 43: 836-841
24. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, Miyazaki S, Maeda K, Tatemichi N, Takei Y (1996). Modification of β2M with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 49: 861-867
25. Miyata T, Inagi R, Iida Y, Sato M, Yamada N, Oda O, Maeda K and Seo H (1994). Involvement of B2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alfa and interleukin-1 J Clin Invest 93, 521-528
26. Linke RP, Hampl H, Lobeck H, Ritz E, Bommer J, Waldherr R and Eulitz M (1989). Lysine-specific cleavage of beta-2-microglobulin in amyloid deposits associated with hemodialysis. Kidney Int 36, 675-681
27. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y and Kondo T (1996). Amyloid β;2-microglobulin is modified with N-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 50, 1303-1309
28. Campistol JM, Bernard D, Papastoitsis G, Sole M, Kasirsky J and Skinner M (1996). Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysisamyloidosis. Kidney Int 50, 1262-1267
29. 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92, 1243-1252
30. Giardino I, Edelstein D and Brownlee M (1994). Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J Clin Invest 94, 110-117